Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: The FNIH NIMBLE project plan.

References

  1. Younossi, Z. M. J. Hepat. 70, 531–544 (2019).

    Article  Google Scholar 

  2. Dulai, P. S. et al. Hepatology 65, 1557–1565 (2017).

    CAS  Article  Google Scholar 

  3. Kleiner, D. E. et al. JAMA Netw. Open 2, e1912565 (2019).

    Article  Google Scholar 

  4. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biomarker-qualification-evidentiary-framework (USDA, 2018).

  5. Menetski, J. P. et al. Nat. Rev. Drug Discov. 18, 567–568 (2019).

    CAS  Article  Google Scholar 

  6. Zhang, Y. N. et al. J. Magn. Reson. Imaging 51, 25–42 (2020).

    Article  Google Scholar 

  7. Li, Q., Dhyani, M., Grajo, J. R., Sirlin, C. & Samir, A. E. World J. Hepatol. 10, 530–542 (2018).

    Article  Google Scholar 

  8. FDA. Biomarker Qualification Submission DDTBMQ000084: Circulating Biomarkers for Diagnosis of Nonalcoholic Steatohepatitis (NASH) (FDA, 2020).

  9. FDA. Biomarker Qualification Submission DDTBMQ000112: Imaging Biomarkers for Diagnosis of Nonalcoholic Steatohepatitis (FDA, 2021).

Download references

Acknowledgements

We acknowledge support from the Global Liver Institute, USA, and the US FDA. The NIMBLE project is sponsored by the FNIH and is a public–private partnership supported by multiple entities including AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Echosens, GE Healthcare, Genentech, Gilead Sciences, Intercept Pharmaceuticals, Novo Nordisk, Pfizer and Takeda Development Center Americas. Key collaborators who provide in-kind support to NIMBLE include AMRA Medical, Canon Medical Systems USA, Echosens, GENFIT, GE Healthcare, Nordic Bioscience, OWL Metabolomics, Philips Ultrasound, P-Value, Hologic SuperSonic Imagine, Siemens Healthineers and Siemens Medical Solutions USA.

Author information

Authors and Affiliations

Authors

Contributions

The manuscript was drafted by A.J.S. and was substantially revised and critiqued by all of the authors and approved by the authors prior to submission. The authors take full responsibility for the contents of this manuscript.

Corresponding author

Correspondence to Arun J. Sanyal.

Ethics declarations

Competing interests

A.J.S. is President of Sanyal Biotechnology, has stock options in Genfit, Akarna, Tiziana, Indalo, Exhalenz and Durect; receives royalties from Elsevier and UptoDate; and has served as a consultant to Astra Zeneca, Janssen, Gilead, Terns, Histoindex, Path-AI, Inventiva, Amgen, Regeneron, Genentech, Merck, Valeant, Boehringer-Ingelheim, Bristol Myers Squibb, Fractyl, Lilly, Hemoshear, Novartis, Novo Nordisk, Pfizer, Intercept and Genfit. Virginia Commonwealth University has received grant support from Gilead, Salix, Tobira, Eli Lilly, Novo Nordisk, Celgene, Viking, Madrigal, Galmed, Pfizer, Bristol Myers, Intercept, Merck, Astra Zeneca, Mallinckrodt and Novartis. S.S.S. is an employee of Astra Zeneca. R.A.C. is employed by Regeneron Pharmaceuticals and is owner of restricted stock units from Regeneron and Pfizer. A.E.S. has served as a compensated consultant for Astra Zeneca, Bracco Diagnostics, Bristol Myers Squibb, General Electric, Gerson Lehman Group, Guidepoint Global Advisors, Supersonic Imagine, Novartis, Pfizer, Philips, Parexel Informatics and WorldCare Clinical; holds stock options in Remedy Medical, Rhino Healthtech and Ochre Bio; is a co-founder of, and holds equity in, Avira, Autonomus, Evidence Based Psychology, Klea, Katharos Laboratories, Quantix Bio and Sonoluminous; receives royalties from Elsevier and Katharos Laboratories; holds advisory board or committee memberships for General Electric, the FNIH and the Sano Center for Computational Personalized Medicine; and is a member of the Board of Governors of the American Institute for Ultrasound in Medicine. Massachusetts General Hospital has received research grant support and/or equipment for projects that A.E.S. has led from the Analogic Corporation, Canon, Echosens, General Electric, Hitachi, Philips, Siemens, Supersonic Imagine/Hologic, Toshiba Medical Systems, the US Department of Defense, Fujifilm Healthcare, the Foundation for the National Institutes of Health, Partners Healthcare, Toshiba Medical Systems and Siemens Medical Systems. C.B.S. reports grants from General Electric, Siemens, Philips, Bayer, the FNIH, Gilead and Pfizer (grant is to University of Wisconsin–Madison (UW-Madison); the University of California, San Diego (UCSD), is a subcontract to UW-Madison); personal consultation fees from Blade, Boehringer and Epigenomics; consultation under the auspices of the University to AMRA, BMS, Exact Sciences, GE Digital, IBM-Watson, and Pfizer; lab service agreements from Enanta, Gilead, ICON, Intercept, Nusirt, Shire, Synageva and Takeda; royalties from Wolters Kluwer for educational material outside the submitted work; honoraria to his institution, UCSD, from Medscape for educational material outside the submitted work; ownership of stock options in Livivos; and an unpaid position on an advisory board to Quantix Bio. S.P.S. is employed by Pfizer and is owner of restricted stock units from Pfizer. R.L. is co-founder of Liponexus, and serves as a consultant for Alnylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, Astra Zeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Inipharm, Intercept, Ionis, Janssen, Madrigal, Metacrine, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Sagimet, 89 bio and Viking Therapeutics. UCSD has received grant support from Allergan, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead, Intercept, Inventiva, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Pfizer and Siemens. K.J.F. reports grant support from General Electric, Bayer, Pfizer and Median; institutional consulting with General Electric; personal consulting with Bayer; an unpaid position on the advisory board of Quantix Bio; and lab service agreements from Enanta, Gilead, ICON, Intercept, Nusirt, Shire, Synageva and Takeda.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sanyal, A.J., Shankar, S.S., Calle, R.A. et al. Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project. Nat Med 28, 430–432 (2022). https://doi.org/10.1038/s41591-021-01652-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-021-01652-8

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing